Anshul founded and steered PF to become a prominent global consultancy specializing in biologics and advanced therapy engineering with 200+ professionals. Anshul’s role extends to overseeing all corporate legal matters as General Counsel. Under Anshul’s guidance, PF pioneered the industrialization of groundbreaking therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Additionally, Anshul led PF in acquiring and conducting due diligence on other engineering consulting firms, bolstering the company’s ability to offer comprehensive solutions to drug developers facing manufacturing and technical challenges. PF’s recent achievements include leading 50+ facility builds with a total capital investment exceeding $5 billion, managing 200+ capital projects, and collaborating with 100+ life science companies.
In 2020, Precision Medicine Group acquired PF, making it the cornerstone of Precision ADVANCE. ADVANCE is a collection of services within Precision, uniquely focused on addressing the intricate aspects of research, clinical development, regulatory compliance, manufacturing, and commercialization required to successfully bring complex, innovative therapies to market. Anshul’s commitment to advancing next-generation medicines extends to various boards and philanthropic organizations, including IQHQ, Alliance for Regenerative Medicines, Alliance for mRNA Medicines, Institute for Life Changing Medicines and several patient-advocacy organizations.
Before his tenure at PF, Anshul was an attorney and founded several digital agencies. He was a patent litigator at Jones Day and dedicated pro bono work to help persecuted refugees attain asylum in the United States. He graduated from Purdue University with a Bachelor’s in Computer and Electrical Engineering and earned his law degree from John Marshall Law School. During law school, he clerked for a federal judge in the Northern District of Illinois and was Editor-in-Chief of the Review of Intellectual Property Law.